Want to see JP:4598 full AI Analyst Report?
4598 Stock Chart & Stats
¥507.00
-¥3.00(-0.55%)
At close: 4:00 PM EST
¥507.00
-¥3.00(-0.55%)
Day’s Range― - ―
52-Week Range¥100.00 - ¥760.00
Previous CloseN/A
Volume237.90K
Average Volume (3M)379.72K
Market Cap
¥1.49B
Enterprise Value¥1.55B
Total Cash (Recent Filing)¥145.45M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-140.45
Shares Outstanding14,305,000
10 Day Avg. Volume693,770
30 Day Avg. Volume379,723
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)66.43
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No DebtAbsence of debt removes recurring interest and principal obligations, lowering near-term default risk and preserving financial flexibility. For a development-stage biotech, no leverage makes it easier to prioritize R&D or seek equity/partner funding without debt covenants constraining programs.
Public Listing (TSE)Being listed on the Tokyo Stock Exchange provides ongoing access to public equity markets, regulatory visibility, and a recognized venue for secondary raises or investor relations. That structural access improves the company's ability to raise capital or attract strategic partners over time.
Lean Operating StructureA very small headcount indicates a lean cost base and lower fixed payroll overhead, which can modestly extend cash runway relative to larger peers. For a research-focused biotech, a compact organization allows focused outsourcing and preserves cash for core clinical or regulatory milestones.
Bears Say
Zero Revenue Since FY2023Sustained absence of revenue removes an internal funding source and forces reliance on external financing, partnerships, or dilutive equity. Over the medium term, this increases execution risk for development programs and heightens funding and dilution pressures if capital markets are constrained.
Severe Cash BurnPersistent, large negative operating and free cash flow rapidly depletes liquidity and necessitates repeated financing. This structural burn limits strategic flexibility, forces prioritization of short-term funding needs, and raises the probability of dilutive equity raises or unfavorable financing terms.
Collapsed Equity And AssetsMaterial erosion of shareholders' equity and total assets weakens the balance sheet, reducing cushion against shocks and limiting collateral for debt. It amplifies financing and counterparty risk, making future fundraising more dilutive and partnerships or licensing deals harder to negotiate on favorable terms.
Delta-Fly Pharma, Inc. News
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥100.00 and its highest was ¥760.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥1.49B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 11 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Delta-Fly Pharma, Inc. released its earnings results on May 15, 2026. The company reported -¥29.73 earnings per share for the quarter, missing the consensus estimate of N/A by -¥29.73.
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 14,305,000 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Delta-Fly Pharma, Inc. reported an EPS of -¥29.73 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.